Literature DB >> 19090776

Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy.

Yukari C Manabe1, Ronan Breen, Tara Perti, Enrico Girardi, Timothy R Sterling.   

Abstract

Antiretroviral therapy (ART) has beneficial effects on mortality and lowers the incidence of diseases caused by opportunistic infections, such as tuberculosis (TB). Although ART has sustained long-term benefits, the risk of TB is high during the first 3 months after ART initiation. Among cases of ART-associated TB, we define "unmasked TB" as that which occurs in patients with reactivation disease who develop clinically recognizable TB after ART with the restoration of previously acquired TB antigen-specific functional immune responses. TB cases with clinical evidence of an inflammatory syndrome are a subset of these unmasked cases, which we define as "unmasked TB-immune reconstitution inflammatory syndrome." With more widespread use of ART in areas with a high prevalence of TB, unmasked TB will likely become more common. TB diagnostics with improved sensitivity and specificity are urgently needed to detect subclinical TB before it is unmasked.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19090776     DOI: 10.1086/595985

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  34 in total

1.  Prevention of Early Mortality by Presumptive Tuberculosis Therapy Study: An Open Label, Randomized Controlled Trial.

Authors:  Yukari C Manabe; William Worodria; Frank van Leth; Harriet Mayanja-Kizza; Afsatou Ndama Traore; Josefo Ferro; Nadine Pakker; Matthias Frank; Martin P Grobusch; Robert Colebunders; Frank Cobelens
Journal:  Am J Trop Med Hyg       Date:  2016-10-17       Impact factor: 2.345

Review 2.  Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection.

Authors:  Paul K Drain; Kristina L Bajema; David Dowdy; Keertan Dheda; Kogieleum Naidoo; Samuel G Schumacher; Shuyi Ma; Erin Meermeier; David M Lewinsohn; David R Sherman
Journal:  Clin Microbiol Rev       Date:  2018-07-18       Impact factor: 26.132

3.  Implementation and operational research: Integrated pre-antiretroviral therapy screening and treatment for tuberculosis and cryptococcal antigenemia.

Authors:  Lincoln Pac; Mara Murray Horwitz; Anne Marion Namutebi; Brandon J Auerbach; Aggrey Semeere; Teddy Namulema; Miriam Schwarz; Robert Bbosa; Allan Muruta; David B Meya; Yukari C Manabe
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

4.  Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa.

Authors:  Sabine M Hermans; Agnes N Kiragga; Petra Schaefer; Andrew Kambugu; Andy I M Hoepelman; Yukari C Manabe
Journal:  PLoS One       Date:  2010-05-07       Impact factor: 3.240

5.  Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings.

Authors:  Agnes N Kiragga; Barbara Castelnuovo; Damalie Nakanjako; Yukari C Manabe
Journal:  J Int AIDS Soc       Date:  2010-11-03       Impact factor: 5.396

6.  Immunologic markers as predictors of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV and tuberculosis coinfected persons in Thailand.

Authors:  Hong Van Tieu; Jintanat Ananworanich; Anchalee Avihingsanon; Wichitra Apateerapong; Sunee Sirivichayakul; Umaporn Siangphoe; Sukonsri Klongugkara; Benjawan Boonchokchai; Scott M Hammer; Weerawat Manosuthi
Journal:  AIDS Res Hum Retroviruses       Date:  2009-11       Impact factor: 2.205

7.  Tuberculosis after one year of combination antiretroviral therapy in Nigeria: a retrospective cohort study.

Authors:  Maxwell O Akanbi; Chad J Achenbach; Joe Feinglass; Babafemi Taiwo; Adamu Onu; Mai T Pho; Oche Agbaji; Phyllis Kanki; Robert L Murphy
Journal:  AIDS Res Hum Retroviruses       Date:  2013-02-25       Impact factor: 2.205

Review 8.  Human immunodeficiency virus-associated tuberculosis: update on prevention and treatment.

Authors:  Kerry L Dierberg; Richard E Chaisson
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

Review 9.  Epidemiology of HIV-associated tuberculosis.

Authors:  Stephen D Lawn; Gavin Churchyard
Journal:  Curr Opin HIV AIDS       Date:  2009-07       Impact factor: 4.283

10.  Inpatient health services utilization among HIV-infected adult patients in care 2002-2007.

Authors:  Baligh R Yehia; John A Fleishman; Perrin L Hicks; Michelande Ridore; Richard D Moore; Kelly A Gebo
Journal:  J Acquir Immune Defic Syndr       Date:  2010-03       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.